From its early days as one the first suppliers of animal models for research in 1947, Charles River Laboratories (CRL) has developed into a brand supporting the Pharma industry’s drug discovery and development programs. CRL’s market penetration is such that it can claim to work with all of the world’s top drug makers in some aspect via its extensive range of products and services.
The key to its success has been a well planned and orchestrated M&A strategy, which focuses on providing its client base with additional products/services that align with their discovery and development goals. CRL’s latest acquisition was the $800M purchase of MPI Research in February 2018. What differentiates CRL is its philosophy of pursuing acquisitions of both large and small organisations. This strategy that stands in stark contrast to several competitors, who seek to dominate channels to market and offer scale benefit returns via an M&A strategy focused on large value acquisitions.
The CRL strategy over the last 5 years have acquired a number of value-added services including: